A swift big pharma endorsement for Kiadis
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
Merck joins Covid-19 pack with vaccine and antiviral deals
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
Astrazeneca throws Silence an $80m lifeline
Silence has received an important validation, but making progress could be tough.
Bispecifics keep the business development fires burning
Cytomx’s bispecific Probody approach attracts Astellas in a deal with a seemingly high up-front payment.
Tiziana takes a deep breath and targets Covid-19
Using drugs that can cause or exacerbate lung infections to treat the novel coronavirus – what could go wrong?
Another preclinical thumbs-up for Sangamo’s zinc fingers
The deal between Sangamo and Biogen marks another endorsement of a gene-editing technology that many had written off years ago.
